Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Numerous evidences verified that erlotinib could dramatically improve the PFS and OS of
non-small cell lung cancers who harbor EGFR sensitive mutations, however, primary or
secondary resistance will be developed after TKI treatment, doctors do plenty of researches
to overcome TKI resistance. FAST ACT-2 study present that, first line erlotinib combined with
chemotherapy could improved mOS to more than 30 months in NSCLCs who harbor EGFR sensitive
mutations, several study shows that sensitive mutations still exist after TKI resistance,
because of the next generation TKIs(such as BIBW2992) are not avaliable at present, agents
for met amplification(such as Crizotinib) are so expensive that many Chinese patients could
not support. Thus, the investigators hypothesis that, after first line TKI treatment, the
patients who developed TKI resistance could still benefit from second line TKI combined with
chemotherapy.